Press Releases

01.05.2017

Pfizer Announces Positive Top-Line Results from the Comparative REFLECTIONS B538-02 Study for PF-06410293, a Potential Biosimilar to Humira®1 (adalimumab)

01.04.2017

Spark Therapeutics Announces $15 Million Milestone Payment from Pfizer for Progress in Hemophilia B Gene Therapy Program

01.03.2017

Pfizer Invites Public To View And Listen To Webcast Of January 31 Conference Call With Analysts

12.22.2016

Pfizer Completes Acquisition of Small Molecule Anti-Infective Business From AstraZeneca

12.21.2016

BioInvent announces Cancer Immunotherapy Research Collaboration and License Agreement with Pfizer and issues new shares to Pfizer

12.21.2016

Circle Pharma, developer of macrocyclic peptide therapeutics, announces Series A financing and appoints Walter H. Moos, Ph.D., to its board

12.21.2016

FDA Accepts Supplemental New Drug Application for Pfizer’s IBRANCE® (palbociclib) in HR+, HER2- Metastatic Breast Cancer

12.20.2016

Draper to Build Preclinical Microphysiological Systems with Pfizer to Help Predict Clinical Outcomes

12.19.2016

Pfizer Presents Data from PALOMA-2 Phase 3 Study Demonstrating Clinical Benefit of IBRANCE® (palbociclib) in Asian Women with ER+, HER2- Metastatic Breast Cancer at ESMO Asia Congress

12.19.2016

Pfizer Receives Approval in the European Union for Nimenrix™ (Meningococcal Group A, C, W-135, and Y Conjugate Vaccine) in Infants Six Weeks of Age and Older

12.16.2016

FDA Approves Removal Of Boxed Warning Regarding Serious Neuropsychiatric Events From CHANTIX® (varenicline) Labeling

12.14.2016

Pfizer Receives FDA Approval for EUCRISA™ (crisaborole), a Novel Non-Steroidal Topical Ointment for Mild to Moderate Atopic Dermatitis (Eczema)